Boston Scientific Predicts IVT Revenues Will Balloon Following Acquisition
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific remains committed to ongoing merger negotiations with Medinol despite its $345 mil. cash acquisition of Interventional Technologies, which gives it access to IVT's LP coronary stent line.
You may also be interested in...
Boston Scientific Looking To Expand Urology/Gynecology Product Offerings
Boston Scientific remains open to the possibility of making an acquisition in the urology or gynecology area to boost the current 8-10% rate of revenue growth.
Boston Scientific Looking To Expand Urology/Gynecology Product Offerings
Boston Scientific remains open to the possibility of making an acquisition in the urology or gynecology area to boost the current 8-10% rate of revenue growth.
Medtronic Rapid Exchange Stent Systems Require License For U.S. Marketing
Medtronic would need to pursue a license agreement with Boston Scientific in order to keep its rapid exchange coronary stent systems on the U.S. market, following an adverse arbitration panel ruling July 18.